Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma.

Official record

Identifier

NCT07739654

Recruiting locations

country

Pakistan

Interventions studied

CisplatinCisplatin

Lead sponsor

King Edward Medical University

Target enrolment

74 participants

Study type

INTERVENTIONAL

Phase

Phase 3

Status

Recruiting

First posted

Jul 31, 2026

Last updated on the registry

Jul 31, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Histologically confirmed relapsed or refractory DLBCL
* Adults ≥ 18 years
* At least one prior line of therapy for lymphoma
* ECOG performance status 0-2
* Ability to provide informed consent and comply with study requirements
* Adequate organ function:
* Hematologic: ANC ≥ 1,000 cells/mm³, Platelets ≥ 75,000 cells/mm³
* Renal: Serum creatinine ≤ 1.5 × ULN
* Hepatic: Total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (if no liver metastases)

Exclusion Criteria:

* History of other malignancies within last 5 years (except non-melanoma skin cancer or localized prostate cancer)
* Pregnant or breastfeeding women
* Significant uncontrolled medical conditions (e.g., cardiovascular disease, uncontrolled diabetes)
* Receipt of investigational agents within 30 days prior to enrollment
* Known severe allergic reactions to DHAP components (dexamethasone, cytarabine, cisplatin)
* Concurrent anti-cancer treatments (chemotherapy, radiotherapy) during study period

Indexed under

Lymphoma